Saredutant

DRUG4 trials

Sponsors

Sanofi

Conditions

AnxietyDepressive DisorderGeneralized Anxiety

Phase 3

A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder

CompletedNCT00390650

Start: 2006-10-31End: 2007-11-30Updated: 2011-04-06

An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder

CompletedNCT00390533

SanofiGeneralized Anxiety

Start: 2006-09-30End: 2008-02-29Updated: 2016-05-24

An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder

CompletedNCT00417118

SanofiGeneralized Anxiety

Start: 2006-12-31End: 2008-04-30Updated: 2016-05-24

A Study Evaluating the Safety and Tolerability of Abrupt Discontinuation of Saredutant in Patients With Depression

CompletedNCT00429260

SanofiDepressive Disorder

Start: 2007-01-31End: 2007-06-30Updated: 2012-02-17